MMedication Read More MRK Pins Hopes on New PAH Drug Winrevair Amid Looming Keytruda LOEJuly 3, 2025 Merck’s MRK blockbuster PD-L1 inhibitor, Keytruda, approved for several types of cancer indications, is the company’s biggest revenue…